<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">8806785</journal-id>
<journal-id journal-id-type="pubmed-jr-id">4226</journal-id>
<journal-id journal-id-type="nlm-ta">Glia</journal-id>
<journal-id journal-id-type="iso-abbrev">Glia</journal-id>
<journal-title-group>
<journal-title>Glia</journal-title>
</journal-title-group>
<issn pub-type="ppub">0894-1491</issn>
<issn pub-type="epub">1098-1136</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">28856719</article-id>
<article-id pub-id-type="pmc">5766030</article-id>
<article-id pub-id-type="doi">10.1002/glia.23209</article-id>
<article-id pub-id-type="manuscript">NIHMS929551</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Oligodendrocyte <italic>RasG12V</italic> Expressed in its Endogenous Locus Disrupts Myelin Structure Through Increased MAPK, Nitric Oxide, and Notch Signaling</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Titus</surname>
<given-names>Haley E.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="author-notes" rid="FN2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>López-Juárez</surname>
<given-names>Alejandro</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="author-notes" rid="FN2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Silbak</surname>
<given-names>Sadiq H.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Rizvi</surname>
<given-names>Tilat A.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Bogard</surname>
<given-names>Madeleine</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ratner</surname>
<given-names>Nancy</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="author-notes" rid="FN1">*</xref>
</contrib>
</contrib-group>
<aff id="A1">
<label>1</label>Division of Experimental Hematology and Cancer Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 45229, USA</aff>
<author-notes>
<corresp id="FN1"><label>*</label><bold>Corresponding Author</bold>: Nancy Ratner, <email>Nancy.Ratner@cchmc.org</email>, Mailing address: 3333 Burnet Ave., Cincinnati Children's Hospital, Cincinnati, OH, 45229-7013, Telephone: 513-636-9469, Fax: 513-803-1083</corresp>
<fn fn-type="equal" id="FN2">
<label>2</label>
<p id="P1">These authors contributed equally to this work.</p>
</fn>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>8</day>
<month>1</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="epub">
<day>30</day>
<month>8</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="ppub">
<month>12</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>01</day>
<month>12</month>
<year>2018</year>
</pub-date>
<volume>65</volume>
<issue>12</issue>
<fpage>1990</fpage>
<lpage>2002</lpage>
<!--elocation-id from pubmed: 10.1002/glia.23209-->
<abstract>
<p id="P2">Costello syndrome (CS) is a gain of function Rasopathy caused by heterozygous activating mutations in the <italic>HRAS</italic> gene. Patients show brain dysfunction that can include abnormal brain white matter. Transgenic activation of <italic>HRas</italic> in the entire mouse oligodendrocyte lineage resulted in myelin defects and behavioral abnormalities, suggesting roles for disrupted myelin in CS brain dysfunction. Here we studied a mouse model in which the endogenous <italic>HRas</italic> gene is conditionally replaced by mutant <italic>HRasG12V</italic> in mature oligodendrocytes, to separate effects in mature myelinating cells from developmental events. Increased myelin thickness due to decompaction was detectable within one month of <italic>HRasG12V</italic> expression in the corpus callosum of adult mice. Increases in active ERK and Nitric Oxide (NO) were present in <italic>HRas</italic> mutants and inhibition of NO synthase (NOS) or MEK each partially rescued myelin decompaction. In addition, genetic or pharmacologic inhibition of Notch signaling improved myelin compaction. Complete rescue of myelin structure required dual drug treatments combining MAPK, NO or Notch inhibition; with MEK + NOS blockade producing the most robust effect. We suggest that individual or concomitant blockade of these pathways in Costello syndrome patients may improve aspects of brain function.</p>
</abstract>
<kwd-group>
<kwd>Myelin</kwd>
<kwd>Rasopathy</kwd>
<kwd>Notch</kwd>
<kwd>Ras</kwd>
<kwd>Nitric Oxide</kwd>
<kwd>Costello Syndrome</kwd>
<kwd>Oligodendrocyte</kwd>
</kwd-group>
</article-meta>
</front>
</article>
</pmc-articleset>